Cancer Research Annual Meeting 2010 EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Cancer Research 67, 1645, February 15, 2007. doi: 10.1158/0008-5472.CAN-06-2980
© 2007 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Folgiero, V.
Right arrow Articles by Mercurio, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Folgiero, V.
Right arrow Articles by Mercurio, A. M.

Cell, Tumor, and Stem Cell Biology

The {alpha}6ß4 Integrin Can Regulate ErbB-3 Expression: Implications for {alpha}6ß4 Signaling and Function

Valentina Folgiero1, Robin E. Bachelder2, Giulia Bon1, Ada Sacchi1, Rita Falcioni1 and Arthur M. Mercurio3

1 Molecular Oncogenesis Laboratory, Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy; 2 Department of Pathology, Duke University Medical Center, Durham, North Carolina; and 3 Department of Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts

Requests for reprints: Rita Falcioni, Molecular Oncogenesis Laboratory, Department of Experimental Oncology, Regina Elena Cancer Institute, Via delle Messi d'Oro 156, 00158 Rome, Italy. Phone: 39-06-5266-2535; Fax: 39-06-5266-2505; E-mail: falcioni{at}ifo.it.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The integrin {alpha}6ß4 has been shown to facilitate key functions of carcinoma cells, including their ability to migrate, invade, and evade apoptosis. The mechanism involved seems to be a profound effect of {alpha}6ß4 on specific signaling pathways, especially the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. An intimate relationship between {alpha}6ß4 and growth factor receptors may explain this effect of {alpha}6ß4 on signaling. Previously, we showed that {alpha}6ß4 and ErbB-2 can function synergistically to activate the PI3K/Akt pathway. Given that ErbB-2 can activate PI3K only when it heterodimerizes with other members of the epidermal growth factor receptor family, these data imply that other receptors cooperate in this process. Here, we report that {alpha}6ß4 can regulate the expression of ErbB-3 using several different models and that the consequent formation of an ErbB-2/ErbB-3 heterodimer promotes the {alpha}6ß4-dependent activation of PI3K/Akt and the ability of this integrin to impede apoptosis of carcinoma cells. Our data also support the hypothesis that {alpha}6ß4 can regulate ErbB-3 expression at the translational level as evidenced by the findings that {alpha}6ß4 does not increase ErbB-3 mRNA significantly, and that this regulation is both rapamycin sensitive and dependent on eukaryotic translation initiation factor 4E. These findings provide one mechanism to account for the activation of PI3K by {alpha}6ß4 and they also provide insight into the regulation of ErbB-3 in carcinoma cells. [Cancer Res 2007;67(4):1645–52]


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
The {alpha}6ß4 integrin was identified initially as an epithelial-specific integrin, and it was thought that expression of the ß4 subunit was limited to cells of epithelial origin (1). Subsequent studies in this direction focused on the role of this integrin in epithelial biology and hemidesmosome organization (2, 3). Prior to these studies, however, Falcioni et al. (4) identified a tumor antigen associated with metastasis (TSP-180) that was shown to be identical to the ß4 integrin subunit (5). This work provided the first indication that {alpha}6ß4 may be linked to tumor spread. Subsequently, other studies revealed that expression of {alpha}6ß4 persists in some aggressive carcinomas and that its expression may be linked to the behavior of these tumors (6).

A series of articles published by our laboratories provided the first evidence that {alpha}6ß4 contributes to the functions of carcinoma cells and they elucidated some of the mechanisms involved. Specifically, these studies identified key roles for {alpha}6ß4 in the migration, invasion, and survival of carcinoma cells (7–9). Studies by several other laboratories have substantiated and extended these findings (10). In fact, there is now compelling evidence that {alpha}6ß4 may actually be involved in the formation of some carcinomas (11). It is widely assumed that the distinct signaling properties of {alpha}6ß4 underlie its involvement in these diverse functions of carcinoma cells. Although {alpha}6ß4 has been reported to activate several key signaling molecules in carcinoma cells, its ability to activate phosphatidylinositol 3-kinase (PI3K) has attracted the most attention, especially with regard to its influence on function.

A critical, unresolved issue is the mechanism by which {alpha}6ß4 activates PI3K (12). This mechanism is probably not a direct activation of PI3K by {alpha}6ß4 because the ß4 cytoplasmic domain lacks a consensus sequence for binding the p85 regulatory subunit of PI3K. Studies, to date, on the mechanism by which {alpha}6ß4 activates PI3K have implicated the insulin receptor substrate proteins (IRS-1 and IRS-2), the compartmentalization of {alpha}6ß4 into membrane microdomains, and its synergistic interaction with specific growth factor receptors (13–15). These mechanisms are not mutually exclusive and the ability of {alpha}6ß4 to affect growth factor receptor signaling may encompass all of these postulated mechanisms. In this direction, studies by one of our laboratories provided the first evidence that {alpha}6ß4 may associate with ErbB-2 (16), an orphan receptor of the epidermal growth factor receptor (EGFR) family, on the surface of some breast carcinoma cell lines. Subsequent studies using a 3T3 cell model system showed that both {alpha}6ß4 and ErbB-2 are required for PI3K activation and the stimulation of chemoinvasion (17). Given that ErbB-2 is thought to function only when it heterodimerizes with other members of the EGFR family, these data imply that other receptors cooperate in this process.

In the current study, we investigated the relationship between {alpha}6ß4 and ErbB signaling more rigorously, especially in the context of PI3K activation. Specifically, we focused on ErbB-3, which lacks intrinsic protein tyrosine kinase activity but possesses in its cytoplasmic tail six consensus binding sites for the SH2 domain of the p85 regulatory subunit of PI3K (18). Among the EGFR family, the ErbB-2/ErbB-3 heterodimer is the strongest stimulator of the PI3K activity (19) and the overexpression of both proteins promotes breast carcinoma proliferation and survival (20, 21). Our data reveal that {alpha}6ß4 can regulate the expression of ErbB-3 at the level of protein translation, resulting in a significant induction of ErbB-2/ErbB-3 heterodimerization and consequent activation of PI3K. These findings provide one mechanism to account for the activation of PI3K by {alpha}6ß4 and they also provide insight into the regulation of ErbB-3 in carcinoma cells.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Cell lines. The human breast carcinoma cell lines MDA-MB-435 and MCF7 were obtained from the American Type Culture Collection (Manassas, VA) and maintained in RPMI medium supplemented with 10% FCS (Invitrogen, Milan, Italy). The generation of MDA-MB-435 subclones that express the {alpha}6ß4 integrin and NIH 3T3 cells that express ErbB-2 and the {alpha}6ß4 integrin has previously been described (12, 17). The generation of MCF7 scrambled short hairpin RNA (scr-shRNA) and MCF7/ß4 shRNA cell subclones that endogenously express {alpha}6ß4 integrin or are depleted for the expression of {alpha}6ß4 integrin has previously been described (22). The rat bladder epithelial cell line 804G was kindly donated by Dr. G. Meneguzzi (Faculty of Medicine, Institut National de la Santé et de la Recherche Médicale U634, Nice, France).

Reagents. The ß4 antibodies (439-9B and 450-11A), the {alpha}6 antibody (135-13C), and the ErbB-2 antibody (W6/100) were prepared as described (16, 17). The antibody W6/100 was used for immunoprecipitation experiments. The ErbB-2 antibodies (clone 3B5 and Ab-1) were purchased from BD PharMingen and Oncogene (Milan, Italy) and used in Western blot experiments. The immunoprecipitation experiments were also done with the anti–ErbB-2 (clone 9G6) from Oncogene. The rabbit ErbB-3 antibody (C17) was obtained from Santa Cruz Biotechnology (Milan, Italy). The eukaryotic translation initiation factor 4E (eIF-4E), 4E-BP1, Akt, and phospho-Akt(Ser473) antibodies and the signal transducer and activator of transcription 1 (Stat-1) antibody were purchased from Cell Signaling (Milan, Italy). The {alpha}-tubulin (TU-01), actin (JLA20), and heat shock protein 70 (Hsp70; N27F3-4) antibodies were purchased from BD Biosciences, Immunological Sciences, and Stressgen (Milan, Italy), respectively. FITC- and peroxidase-conjugated immunoglobulin antibodies were purchased from Bio-Rad (Milan, Italy).

A laminin 5–enriched matrix was prepared from 804G cells as previously described (23). In brief, confluent 804G cells in either 100-mm dishes or 96-well plates were washed in sterile PBS and detached from the underlying laminin 5–enriched matrix by treatment for 10 min in 20 mmol/L NH4OH at 4°C and subsequent washing thrice with sterile PBS. Poly-L-lysine (Calbiochem, Milan, Italy) was used as control matrix at a concentration of 10 µg/mL.

RNA interference and antisense experiments. To diminish ErbB-3 expression, MCF7 parental cells and MDA-MB-435/ß4 cells were transiently transfected with the Transit-TKO reagent (Mirus, Madison, WI) with either an ErbB-3 small interfering RNA (siRNA; 5'-GCUCUACGAGAGGUGUGAGTT-3' and 5'-CUCACACCUCUCGUAGAGCTT-3') or a control siRNA (5'-GCGCGCAACUCUACCUCUATT-3' and 5'-UAGAGGUAGAGUUGCGCGCTT-3'). These oligonucleotides were synthesized by Oligoengine, Inc. (Seattle, WA). The cells were transfected with TKO reagent in the presence of serum following the manufacturer's protocol.

To diminish eIF-4E expression, cells were transiently transfected using Lipofectamine (Invitrogen) with the PG-eIF-4E vector (Promega Biotech, Milan, Italy) that carries the sense and antisense oligonucleotides as previously described (24).

Reverse transcription-PCR. Total RNA was prepared from MDA-MB-435/Mock, MDA-MB-435/ß4, MCF7/scr-shRNA, and MCF7/ß4 shRNA cells using RNAzol B according to the manufacturer's procedure (Invitrogen). Reverse transcription-PCR for analysis ErbB-3 mRNA expression was carried out with the following specific primers synthesized by Invitrogen: forward, 5'-GGTGCTGGGCTTGCTTTT-3'; reverse, 5'-CGTGGCTGGAGTTGGTGTTA-3'. Amplified PCR products were electrophoresed on an agarose gel containing ethidium bromide (0.5 µg/mL) and visualized under UV light.

Cell treatments. MCF7/scr and MCF7/siErbB-3 cells were serum starved for 24 h. The cells were detached with trypsin and spread onto a laminin 5–enriched matrix for 20 min. Then, the cells were washed with cold PBS and extracted in SDS buffer [1% SDS, 10% glycerol, 137 mmol/L NaCl, 20 mmol/L Tris-HCl (pH 7.4), 50 mmol/L NaF, 1 mmol/L phenylmethylsulfonyl fluoride (PMSF), 5 mmol/L Na3VO4, 50 mmol/L protease inhibitors (Sigma-Aldrich, Milan, Italy)]. Recombinant human heregulin ß1 (HRG-ß1; 10 ng/mL; R&D Systems, Milan, Italy) was added to the cells that had been serum deprived for 24 h. After 20 min of stimulation, the cells were washed with cold PBS and extracted in NP40 buffer [1% NP40, 10% glycerol, 137 mmol/L NaCl, 20 mmol/L Tris-HCl (pH 7.4), 50 mmol/L NaF, 1 mmol/L PMSF, 5 mmol/L Na3VO4, protease inhibitors]. To induce ErbB-2/ErbB-3 heterodimerization, the cells were stimulated with HRG-ß1 for 10 min before lysis. MDA-MB-435/mock and MDA-MB-435/ß4 cells were plated at a concentration of 1.5 x 106 per 100-mm dish. The next day, the medium was replaced with serum-free medium in the presence of rapamycin 50 nmol/L (Calbiochem) for 30 and 60 min. Then, the cells were washed in PBS and extracted in radioimmunoprecipitation assay buffer [50 mmol/L Tris-HCl (pH 8), 150 mmol/L NaCl, 1% NP40, 0.1% deoxycholate, 0.1% SDS, 1 mmol/L PMSF, 5 mmol/L Na3VO4, 50 mmol/L protease inhibitors].

Apoptosis assay. The MDA-MD 435/ß4/scr, MDA-MB-435/ß4/siErbB-3, MCF7/scr, and MCF7/siErbB-3 cells were serum starved for 24 h. For Annexin V staining, 1 x 106 cells were washed with PBS, centrifuged, and resuspended in 100 µL of Annexin V-FITC labeling solution (Boehringer, Milan, Italy) in the presence of propidium iodide and incubated for 15 min. After washing, the cells were incubated in SA-FLUOS solution for 20 min at 4°C, centrifuged, washed, and analyzed by fluorescence-activated cell sorting (FACS).

Flow cytometry. To assess ErbB-3 surface expression, cells were harvested using citrate saline buffer (0.134 mol/L KCl, 0.015 mol/L Na citrate) and washed twice with cold PBS containing 0.002% EDTA and 10 mmol/L NaN3. Samples (1 x 106) cells were incubated for 1 h at 4°C with saturating concentrations of primary antibody diluted in PBS containing 0.5% bovine serum albumin (BSA). Cells were then washed with PBS containing 0.5% BSA and incubated for 1 h at 4°C with 50 µL of FITC-conjugated secondary antibody [F(ab')2; Cappel, West Chester, PA] diluted 1:20 in PBS/BSA. After washing, cell suspensions were analyzed with a flow cytometer (Epics XL analyzer, Coulter Corp., Miami, FL) after addition of 5 µL of a 1 mg/mL solution of propidium iodide to exclude nonviable cells. At least 1 x 104 cells per sample were analyzed.

Immunoprecipitation and Western blot analysis. Total cell lysates from MCF7/scr and MCF7/ß4 cells were immunoprecipitated with anti–ErbB-2 antibody (clone W6/100) and protein A from Pierce (Milan, Italy). Total protein and immunocomplexes were separated by 8% SDS-PAGE and transferred to nitrocellulose. The proteins were detected by Western blot analysis with anti–ErbB-2 (clone 3B5) and anti–ErbB-3 (clone C-17) antibodies, respectively. Extracts from the cell populations described in the figure legends were separated by SDS-PAGE, transferred to nitrocellulose, and probed with the antibodies described above. Total cell lysates from NIH 3T3 clones were immunoprecipitated with an {alpha}6 antibody and probed with a ß4 antibody.

PI3K activity. To assay PI3K activity, the cells were lysed after serum starvation for 24 h, and aliquots of cell extracts containing equivalent amounts of protein were subjected to a PI3K assay as previously described (17). The phosphorylated lipids were resolved on TLC plates (Merck, Darmstadt, Germany) and subjected to autoradiography.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Expression of {alpha}6ß4 integrin enhances ErbB-3 expression. We assessed the hypothesis that the functional relationship between the {alpha}6ß4 integrin and ErbB-2 involves other members of the EGFR family, especially ErbB-3. To address this hypothesis initially, we used stable transfectants of MDA-MB-435 cells that express the {alpha}6ß4 integrin (12). As shown in Fig. 1A , expression of ß4 integrin in these cells results in a marked induction of ErbB-3 expression. This relationship between {alpha}6ß4 and ErbB-3 was also evaluated in breast carcinoma cells that express endogenous {alpha}6ß4 and ErbB-3 using shRNA. Specifically, ß4 shRNA depleted ß4 expression, as well as ErbB-3 expression, in MCF7 cells (Fig. 1B). In contrast, expression of Hsp70 was not affected by the ß4 shRNA. Importantly, no effect of {alpha}6ß4 on ErbB-2 expression was evident in any of our experiments (Figs. 3A–B and 4B).


Figure 1
View larger version (32K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1. {alpha}6ß4 integrin enhances ErbB-3 expression. Detergent extracts obtained from MDA-MB-435 mock and ß4-transfected cells (A); MCF7 scr-shRNA and ß4 shRNA cells (B); and NIH 3T3/ErbB-2, NIH 3T3/ErbB-2/ß4L, NIH 3T3/ErbB-2/ß4 wild-type, NIH 3T3 parental, and NIH 3T3/ß4 cells (C) were separated by SDS-PAGE and total cell lysates were immunoprecipitated with an {alpha}6 antibody and immunoblotted with a ß4 antibody (top rows) or with ErbB-2 and ErbB-3 antibodies (middle rows). Antibodies specific for Stat-1, Hsp70, and actin were used to validate equivalent amounts of protein in each lane (bottom rows). D, FACS analysis of endogenous {alpha}6 and exogenous ß4L expression in NIH 3T3 cells.

 

Figure 3
View larger version (14K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 3. The {alpha}6ß4 stimulation of Akt activation is dependent on ErbB-3. A, mock and {alpha}6ß4-expressing MDA-MB-435 cells were transiently transfected for 48 h with either ErbB-3–specific or scrambled siRNAs. The cells were then serum starved for 24 h and extracted in detergent. Equivalent amounts of protein were separated by SDS-PAGE and analyzed by immunoblotting to evaluate the relative expression of ErbB-3, ErbB-2, and phospho-Akt (P-Akt). Hsp70 and Akt antibodies were used to validate equivalent loading of protein in each lane. B, MCF7 cells were transiently transfected for 48 h with either ErbB-3–specific or scrambled siRNAs and then serum starved for 24 h. Subsequently, the cells were plated on either laminin 5 (LM5) or poly-L-lysine for the indicated time. Equivalent amounts of protein were resolved by SDS-PAGE and analyzed by immunoblotting to evaluate the relative expression of ErbB-3, ErbB-2, and phospho-Akt. Hsp70 and Akt antibodies were used to validate equivalent loading of protein in each lane. The relative level of phospho-Akt to total Akt was assessed by densitometry using the NIH Image program and this ratio is provided under the phospho-Akt bands for each immunoblot.

 

Figure 4
View larger version (23K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 4. HRG-ß1–dependent ErbB-2/ErbB-3 heterodimerization and Akt activation are influenced by {alpha}6ß4 integrin. A, MCF7 scr and ß4 shRNA cells were serum starved for 24 h. Subsequently, the cells were stimulated with HRG-ß1 for 10 min, washed, and extracted with detergent. Equivalent amounts of protein were incubated with a bead-conjugated ErbB-2 antibody. Immunocomplexes and aliquots of total cell extracts were separated by SDS-PAGE and analyzed by immunoblotting with an ErbB-3 antibody. B, the immunocomplexes and aliquots of total cell extracts were also analyzed by immunoblotting with an ErbB-2 antibody. C, aliquots of cell extracts derived from MCF7 scr and ß4 shRNA cells stimulated with HRG-ß1, as described above, and lysates containing equivalent amount of protein were subjected to a PI3K assay. The phosphorylated lipids were resolved by TLC. D, MDA-MB-435 parental and {alpha}6ß4-expressing cells were transiently transfected for 48 h with either ErbB-3–specific or scrambled siRNAs and then serum starved for 24 h. Subsequently, the cells were stimulated with HRG-ß1 for 20 min, washed, and extracted. Equivalent amounts of protein were separated by SDS-PAGE and analyzed by immunoblotting to evaluate the relative expression of phospho-Akt. An Hsp70 antibody was used to validate equivalent amounts of protein in each lane.

 
The data obtained above were substantiated using an NIH 3T3 cell model system. These cells express neither {alpha}6ß4 nor ErbB-2, and they express a minimal amount of ErbB-3. We previously reported that expression of both {alpha}6ß4 and ErbB-2 in these cells is necessary to activate the PI3K/Akt pathway (17). Based on our hypothesis, we predicted that the expression of these receptors would also result in the consequent expression of ErbB-3. Indeed, expression of both {alpha}6ß4 and ErbB-2 resulted in a substantial increase in ErbB-3 expression (Fig. 1C). Expression of ErbB-2 alone or in combination with a cytoplasmic deletion mutant of ß4 resulted in only a marginal increase in ErbB-3 expression (Fig. 1C). The expression of the wild-type ß4 subunit in the absence of ErbB-2 did not increase ErbB-3 expression (Fig. 1C). We also confirmed heterodimerization between the endogenous {alpha}6 integrin and the exogenous ß4 subunits in both parental and ErbB-2–expressing NIH 3T3 cells (Fig. 1C, top). The expression of the {alpha}6 subunit and the ß4 subunit with a deleted cytoplasmic domain (ß4L) was assessed by FACS analysis (Fig. 1D). The NIH 3T3 clones we used express comparable levels of endogenous {alpha}6 subunit (data not shown).

The survival function of {alpha}6ß4 is dependent on ErbB-3. A key function of {alpha}6ß4 is to protect carcinoma cells from apoptotic stimuli such as growth factor or hormone deprivation (22, 25). To investigate whether the survival function of {alpha}6ß4 is dependent on ErbB-3, we examined the effect of reducing ErbB-3 expression in {alpha}6ß4-expressing carcinoma cells on their survival in serum-deprived conditions. As shown in Fig. 2A , the transfection of MDA-MB-435/ß4 cells with an ErbB-3 siRNA resulted in a 3.5-fold reduction in ErbB-3 expression. As evidence for a role of ErbB-3 in {alpha}6ß4-mediated survival, we observed that ErbB-3 siRNA–transfected MDA-MB-435/ß4 cells exhibited a 2.5-fold increase in Annexin V positivity compared with cells transfected with a scrambled control siRNA. Likewise, a 2-fold increase in cell death, as assessed by propidium iodide staining, was observed in MDA-MB-435/ß4 cells after transfection with ErbB-3 siRNA. To show that the survival function of {alpha}6ß4 in cells that endogenously express this integrin is dependent on ErbB-3, we transfected MCF7 cells with an ErbB-3 siRNA. ErbB-3 siRNA transfectants exhibited a 2.2-fold increase in Annexin V positivity, as well as propidium iodide positivity, indicating a distinct role for ErbB-3 in impeding apoptotic death (Fig. 2B).


Figure 2
View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2. {alpha}6ß4 survival function is dependent on ErbB-3. A, {alpha}6ß4-expressing MDA-MB-435 cells were transiently transfected for 48 h with either ErbB-3–specific or scrambled siRNAs. Subsequently, the cells were serum starved for 24 h and ErbB-3 surface expression was evaluated by flow cytometry. Apoptosis was assessed with Annexin V-FITC and propidium iodide (PI). B, MCF7 cells were transfected transiently for 48 h with either ErbB-3–specific or scrambled siRNAs. After serum starvation for 24 h, total cell proteins were extracted, then the indicated amount of protein was resolved by SDS-PAGE and immunoblotted with ErbB-3– and ErbB-2–specific antibodies (top). Bottom, apoptosis was assessed by Annexin V-FITC and propidium iodide staining in cells that expressed either ErbB-3 or scrambled siRNA. A Stat-1 antibody was used to validate equivalent loading of protein in each lane.

 
ErbB-3 facilitates Akt activation by {alpha}6ß4. The ability of the {alpha}6ß4 integrin to activate the PI3K/Akt pathway is well documented and it underlies many of the functions attributed to this integrin in carcinoma cells (12, 17, 25–27). Given that ErbB-2 lacks the intrinsic ability to activate PI3K because it does not contain p85 binding sites, a logical hypothesis is that the ability of {alpha}6ß4 to activate the PI3K/Akt pathway is linked to its regulation of ErbB-3. Indeed, as shown in Fig. 3A , expression of {alpha}6ß4 in MDA-MB-435 cells results in a significant increase in Akt activation, as assessed by Ser473 phosphorylation, as well as induction of ErbB-3 expression. To evaluate the contribution of ErbB-3 to {alpha}6ß4-mediated Akt activation, an ErbB-3 siRNA was expressed in these cells as described above, which caused a marked diminution of ErbB-3 expression (Fig. 3A). Importantly, this reduction in ErbB-3 expression diminished Akt activation. These data support the hypothesis that ErbB-3 is necessary for the ability of {alpha}6ß4 to activate Akt in these cells. Of note, neither expression of {alpha}6ß4 nor loss of ErbB-3 expression influenced the expression of ErbB-2 in these cells (Fig. 3A).

Given that the {alpha}6ß4 integrin is a receptor for the laminins, including laminin 5, and that ligation of {alpha}6ß4 by laminins can enhance PI3K/Akt signaling, we assessed the role of ErbB-3 in ligand-induced Akt activation by {alpha}6ß4. The attachment of MCF7 cells to laminin 5 for 30 min resulted in a strong stimulation of Akt activity in comparison with cells plated on poly-L-lysine (Fig. 3B). This robust activation of Akt by laminin-5 attachment was reduced by ~80% in MCF7 cells with diminished ErbB-3 expression (Fig. 3B). After 60 min of laminin-5 attachment, however, the activation of Akt in MCF7 scr cells diminished to the basal level and, in siErbB-3 cells, it was almost abrogated. A significant effect of {alpha}6ß4 ligation on either ErbB-3 or ErbB-2 expression was not observed under these conditions.

The ability of heregulin to induce ErbB-2/ErbB-3 heterodimerization and stimulate Akt activation is influenced by {alpha}6ß4. Although ErbB-3 protein has six binding sites to recruit p85, the regulatory subunit of PI3K, its cytoplasmic tail does not have kinase activity and it requires other members, such as ErbB-2 or EGFR, to activate the PI3K/Akt pathway (28). Heregulin is a ligand for ErbB-3 that induces ErbB-2/ErbB-3 heterodimerization (29). As shown in Fig. 4A , HRG-ß1 enhanced the heterodimerization of ErbB-2/ErbB-3 in MCF7 cells as assessed by coimmunoprecipitation. However, heterodimerization was significantly reduced in cells that expressed the ß4 shRNA because ErbB-3 expression was diminished. As mentioned above, loss of ß4 expression had no effect on ErbB-2 expression in these cells (Fig. 4B). We also evaluated whether the increase of ErbB-2/ErbB-3 heterodimerization could affect PI3K activity. To this end, total cell lysates from MCF7 scr-shRNA and ß4 shRNA cells were tested for PI3K activity in the presence or absence of HRG-ß1 stimulation. As shown in Fig. 4C, HRG-ß1 stimulation of MCF7 scr cells resulted in a much more robust activation of PI3K than did stimulation of MCF7/ß4 shRNA (Fig. 4C). Moreover, the basal level of PI3K activity in MCF7 cells that expressed ß4 shRNA was abrogated in the absence of HRG-ß1 stimulation (Fig. 4C).

We also determined the influence of {alpha}6ß4 on the ability of HRG-ß1 to activate Akt using the MDA-MB-435/scr and ß4 transfectants. Heregulin stimulation of MDA-MB-435/ß4 transfectants resulted in a significant increase in Akt phosphorylation in comparison with the untreated cells (Fig. 4D). Interestingly, expression of siErbB-3 in MDA-MB-435/ß4 transfectants strongly reduced Akt activation on HRG-ß1 stimulation to the same level in the absence of stimulation (Fig. 4D). In contrast, parental MDA-MB-435 cells exhibit only a weak increase of Akt phosphorylation after HRG-ß1 stimulation, which is diminished with siErbB-3. These data substantiate the hypothesis that the {alpha}6ß4-dependent regulation of ErbB-3 expression facilitates heregulin signaling in this system through PI3K.

Evidence that {alpha}6ß4 regulates ErbB-3 translation. The data reported in Figs. 1–4 indicate that {alpha}6ß4 can regulate the expression of ErbB-3 protein in several model systems, and they raise the important issue of the mechanism involved. To begin to address this issue, we assessed the expression of ErbB-3 protein to verify whether {alpha}6ß4 may regulate ErbB-3 expression at the translational level. This possibility is substantiated by our previous study showing that {alpha}6ß4 can regulate the activity of eIF-4E and the mammalian target of rapamycin (mTOR)–dependent expression of vascular endothelial growth factor (VEGF; ref. 30). For this reason, we used an antisense eIF-4E oligonucleotide to reduce expression of this factor in both MDA-MB-435/ß4 transfectants and MCF7 cells. Expression of this antisense oligonucleotide in both cell types caused a reduction in ErbB-3 expression in comparison with cells that expressed the sense oligonucleotide (Fig. 5A and B ).


Figure 5
View larger version (11K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 5. {alpha}6ß4 stimulates eIF-4E–dependent ErbB-3 expression. MDA-MB-435/ß4 cells (A) and MCF7 parental cells (B) were transiently transfected with either an eIF-4E antisense oligo–expressing vector or a control vector expressing eIF-4E in the sense orientation. The relative expression of ErbB-3 and eIF-4E was assessed by immunoblotting. Stat-1 and Hsp70 antibodies were used to validate equivalent amounts of protein in each lane.

 
Additional evidence to support the involvement of {alpha}6ß4 in regulating the translation of ErbB-3 was obtained using rapamycin, which is an inhibitor of the mTOR kinase (31). Treatment of MDA-MB-435 cells with 50 nmol/L rapamycin prevented the increase in ErbB-3 that results from expression of {alpha}6ß4 in these cells (Fig. 6A ). Rapamycin treatment also inhibited the phosphorylation of Akt in MDA-MB-435/ß4 cells (Fig. 6A). This result supports a positive feedback loop in which ErbB-3 expression facilitates Akt activation by {alpha}6ß4 (Fig. 6C).


Figure 6
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 6. {alpha}6ß4-mediated expression of ErbB-3 is rapamycin sensitive and requires ErbB-3 itself. A, mock and {alpha}6ß4-expressing MDA-MB-435 cells were plated at a concentration of 1.5 x 106 per 100-mm dish. The next day, the medium was replaced with serum-free medium in the presence of rapamycin (50 nmol/L) for the indicated times. Subsequently, detergent extracts were analyzed by immunoblotting to evaluate ErbB-3 expression and phospho-Akt. An Hsp70 antibody was used to validate equivalent amounts of protein in each lane. B, mock and {alpha}6ß4-expressing MDA-MB-435 cells were transiently transfected for 48 h with either ErbB-3–specific or scrambled siRNAs. After serum starvation for 24 h, cells were extracted and equivalent amounts of proteins were resolved by SDS-PAGE. The expression of ErbB-3, phospho-Akt, and phospho-4E-BP1 was assessed by immunoblotting. An Hsp70 antibody was used to validate equivalent amounts of protein in each lane. C, schematic model that depicts the regulation of ErbB-3 expression by the {alpha}6ß4 integrin in ErbB-2–positive breast cancer cells. The cooperation between {alpha}6ß4 integrin and ErbB-2 activates PI3K/Akt. The initial activation of PI3K/Akt by {alpha}6ß4 integrin activates mTOR, which stimulates the phosphorylation and inactivation of 4E-BP1 and a consequent increase in ErbB-3 translation. The resulting ErbB-2/ErbB-3 heterodimer amplifies PI3K/Akt signaling, which creates a positive feedback loop.

 
Given that the PI3K/Akt pathway is necessary for mTOR activation and our finding that ErbB-2/ErbB-3 mediates the {alpha}6ß4-dependent activation of this pathway in the cells we examined, it follows that ErbB-3 contributes to the regulation of its own expression in a positive feedback loop. To test this hypothesis, we focused on the role of ErbB-3 in the phosphorylation of 4E-BP1. This is a key event in the regulation of protein translation because the phosphorylation of 4E-BP1 by mTOR disrupts the interaction between 4E-BP1 and eIF-4E, enabling eIF-4E to initiate translation (32, 33). As shown in Fig. 6B, expression of {alpha}6ß4 in MDA-MB-435 cells resulted in a marked induction of 4E-BP1 phosphorylation consistent with our previous results (30). Importantly, however, this induction of 4E-BP1 phosphorylation was ablated in cells that expressed the ErbB-3 siRNA. As expected, the ablation of 4E-BP1 phosphorylation in MDA-MB-435/ß4/siErbB-3 cells correlates with a decrease in Akt phosphorylation (Fig. 6B). Our finding that {alpha}6ß4 can regulate the translation of ErbB-3 protein through the PI3K/Akt activity and mTOR pathway provides one mechanism to account for the role of this integrin in tumor survival (Fig. 1C).


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
It is widely assumed that the distinct signaling properties of the {alpha}6ß4 integrin account for its ability to enhance functions associated with carcinoma progression such as invasion and resistance to apoptotic stimuli (22, 34). In this study, we highlight a novel mechanism by which {alpha}6ß4 can effect activation of the PI3K/Akt pathway. This mechanism involves the ability of {alpha}6ß4 to regulate the expression of ErbB-3, and we provide evidence that this regulation occurs at the level of protein translation. The increase in ErbB-2/ErbB-3 heterodimer formation that occurs as a consequence stimulates Akt activity. Indeed, the ability of heregulin, a ErbB-3 ligand, to stimulate PI3K/Akt activity is enhanced markedly in cells that express {alpha}6ß4. Moreover, our data implicate ErbB-3 in the reported ability of {alpha}6ß4 to protect carcinoma cells from apoptotic stimuli (30). Although previous studies implicated {alpha}6ß4 in the facilitation of growth factor receptor signaling (6, 9), ours is the first study to show that this integrin can promote such signaling by regulating the expression of a specific growth factor receptor.

The data reported here are a direct extension of our previous work that showed an interaction between {alpha}6ß4 and ErbB-2 in breast carcinoma cell lines and revealed the necessity of ErbB-2 for the {alpha}6ß4-dependent activation of the PI3K/Akt pathway and for {alpha}6ß4-mediated functions such as invasion and survival (12, 16, 17, 30). Given that ErbB-2 is thought to function only when it heterodimerizes with other members of the EGFR family (35), the "missing link" in our previous studies was the identification of an ErbB-2 heterodimer that facilitates {alpha}6ß4-dependent functions. Clearly, ErbB-3 is one EGFR family member that can serve in this capacity, a finding that is highly relevant because both the ErbB-2/ErbB-3 heterodimer (36, 37) and {alpha}6ß4 (22, 34) have been implicated in breast cancer progression and metastasis. It is also worth noting that ours is the first study to implicate ErbB-3 directly in the survival of breast carcinoma cells.

Our conclusion that {alpha}6ß4 can regulate ErbB-3 expression and promote ErbB-2/ErbB-3 heterodimer formation and signaling is based on evidence obtained from carcinoma cells that express endogenous {alpha}6ß4 and ErbB-2/ErbB-3, carcinoma cells that lack expression of either {alpha}6ß4 or ErbB-3, as well as a 3T3 cell model system. The inference could be made from these results that all breast carcinoma cells that express {alpha}6ß4 also express ErbB-3 and, conversely, that all breast carcinoma cells that express ErbB-3 also express {alpha}6ß4. Most likely, however, the correlation between {alpha}6ß4 and ErbB-3 expression is not absolute and other factors influence the expression of these receptors. For example, MDA-MB-231 cells express {alpha}6ß4 but not ErbB-3. A likely explanation for this observation is that these cells express the Nrdp1 ubiquitin ligase that promotes ErbB-3 degradation (38). Interestingly, these cells, unlike the cells examined in this study, express EGFR, raising the possibility that EGFR may promote {alpha}6ß4 signaling in some breast carcinoma cells. Further studies are needed to assess coordinate expression of {alpha}6ß4 and EGFR family members in different types and stages of human breast cancers.

An important observation is that {alpha}6ß4 can regulate the translation of ErbB-3 as evidenced by the findings that {alpha}6ß4 regulates ErbB-3 protein expression, which is dependent on eIF-4E and sensitive to rapamycin. This conclusion is buttressed by our previous study showing that {alpha}6ß4 can stimulate mTOR activation and 4E-BP1 phosphorylation in breast carcinoma cells, resulting in increased VEGF translation (30). In the context of our current data, it is interesting to note that ErbB-2/ErbB-3 heterodimers are potent stimulators of VEGF expression in endothelial cells (39). Given our previous work indicating that VEGF is an autocrine survival factor for breast carcinoma cells (30), it is worth considering the possibility that {alpha}6ß4-mediated ErbB-2/ErbB-3 signaling promotes breast carcinoma survival by elevating VEGF expression.

The hypothesis can be formulated based on our past and current results that the ability of {alpha}6ß4 to enhance the translation of key growth factors and receptors underlies the contribution of this integrin to carcinoma biology. In a recent test of this hypothesis, we observed that ablation of {alpha}6ß4 expression by shRNA in an aggressive and metastatic breast carcinoma cell line significantly impaired the ability of these cells to form xenograft tumors (34) and it also resulted in a marked reduction in VEGF expression in tumors that did form. Reexpression of ß4 in these ß4 shRNA cells restored both VEGF expression and tumor formation (34). It will be informative to assess {alpha}6ß4-dependent ErbB-3 expression in a similar fashion.

Insight into the mechanism by which {alpha}6ß4 can activate the PI3K/Akt pathway is provided by our data. This mechanism is probably not a direct activation of PI3K by {alpha}6ß4 because the ß4 cytoplasmic domain lacks a consensus sequence for binding the p85 regulatory subunit of PI3K. Possible mechanisms that have been proposed include the involvement of insulin receptor substrate proteins (IRS-1 and IRS-2), which contain multiple PI3K binding motifs and are tyrosine phosphorylated and bind to PI3K on ligation of {alpha}6ß4 (13). In addition, the compartmentalization of {alpha}6ß4 into lipid rafts may facilitate interactions with tyrosine kinases that can activate PI3K (40). Our results indicate that the activation of PI3K/Akt by {alpha}6ß4 can be indirect and occur through the {alpha}6ß4-dependent regulation of ErbB-3 and the formation of an ErbB-2/ErbB-3 heterodimer that promotes PI3K/Akt activation. This mechanism is attractive because ErbB-3 contains six consensus binding sites for the SH2 domain of p85 (18), the ErbB-2/ErbB-3 heterodimer is known to be a very potent stimulator of PI3K activity (19), and this heterodimer is frequently expressed in breast cancer (36). Nonetheless, a more direct activation of PI3K/Akt by {alpha}6ß4 must occur if we assume that the PI3K/Akt pathway is involved in the regulation of protein (ErbB-3) translation. The increase in ErbB-3 expression that does occur in response to {alpha}6ß4, however, would enhance and sustain PI3K/Akt signaling in a positive feedback mode. Our data, in fact, support this model. As shown in Fig. 6B, expression of {alpha}6ß4 in MDA-MB-435 cells stimulates the phosphorylation of 4E-BP1, a key event in the regulation of protein translation, but this phosphorylation is inhibited dramatically by the expression of an siRNA for ErbB-3. A conclusion can be drawn from these data that ErbB-3 facilitates its own expression because of its ability to heterodimerize with ErbB-2 and enhance PI3K/Akt activation in this positive feedback mode.

In summary, the data we report substantiate the hypothesis that the function and signaling properties of the {alpha}6ß4 integrin in breast carcinoma cells are intimately associated with the EGFR family. These data also support the possibility that the effect of {alpha}6ß4 on the functions of carcinoma cells is mediated, in part, by the ability of this integrin to enhance the translation of key growth factors and growth factor receptors.


   Acknowledgments
 
Grant support: Italian Association for Cancer Research and Ministero della Salute (R. Falcioni) and NIH grants CA80789 (A.M. Mercurio) and CA93855 (R.E. Bachelder). G. Bon is recipient of a fellowship from Federazione Italiana Ricerca sul Cancro (FIRC).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Oreste Segatto, Sergio Anastasi, and John Koland for valuable discussion; and Xuena Lin, Melissa Wendt, Selene Di Carlo, and Stefano Iacovelli for their contributions to this work.

Received 8/11/06. Revised 10/26/06. Accepted 12/ 7/06.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Sonnenberg A, Calafat J, Janssen H, et al. Integrin {alpha}6/ß4 complex is located in hemidesmosomes, suggesting a major role in epidermal cell-basement membrane adhesion. J Cell Biol 1991;113:907–17.[Abstract/Free Full Text]
  2. Schaapveld RO, Borradori L, Geerts D, et al. Hemidesmosomes formation is initiated by ß4 integrin subunit, requires complex of ß4 and HD1/plectin, and involves a direct interaction between ß4 and the bullous pemphigoid antigene 180. J Cell Biol 1998;142:271–84.[Abstract/Free Full Text]
  3. Borradori L, Sonnenberg A. Structure and function of hemidesmosomes: more than simple adhesion complexes. J Invest Dermatol 1999;112:411–8.[CrossRef][Medline]
  4. Falcioni R, Sacchi A, Resau J, Kennel SJ. Monoclonal antibody to human carcinoma-associated protein complex: quantitation in normal and tumor tissue. Cancer Res 1988;48:816–21.[Abstract/Free Full Text]
  5. Kennel SJ, Foote LJ, Falcioni R, et al. Analysis of the tumor-associated antigen TSP-180. Identity with {alpha}6-ß4 in the integrin superfamily. J Biol Chem 1989;264:15515–21.[Abstract/Free Full Text]
  6. Guo W, Giancotti FG. Integrin signalling during tumor progression. Nat Rev Mol Cell Biol 2004;5:816–26.[CrossRef][Medline]
  7. Mercurio AM, Rabinovitz I, Shaw LM. The {alpha}6ß4 integrin and epithelial cell migration. Curr Opin Cell Biol 2001;13:541–5.[CrossRef][Medline]
  8. Mercurio AM, Bachelder RE, Chung J, et al. Integrin laminin receptors and breast carcinoma progression. J Mammary Gland Biol Neoplasia 2001;6:299–309.[CrossRef][Medline]
  9. Mercurio AM, Rabinovitz I. Towards a mechanistic understanding of tumor invasion-lesson from the {alpha}6ß4 integrin. Seminar Cancer Biol 2001;11:129–41.
  10. Giannelli G, Astigiano S, Antonaci S, et al. Role of the {alpha}3ß1 and {alpha}6ß4 integrins in tumor invasion. Clin Exp Metastasis 2002;19:217–23.[CrossRef][Medline]
  11. Berotti A, Comoglio PM, Trusolino L. ß4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. Cancer Res 2005;65:10674–9.[Abstract/Free Full Text]
  12. Shaw LM, Rabinovitz I, Wang HH, Toker A, Mercurio AM. Activation of phosphoinositide 3-OH kinase by the {alpha}6ß4 integrin promotes carcinoma invasion. Cell 1997;91:949–60.[CrossRef][Medline]
  13. Shaw LM. Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the {alpha}6ß4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion. Mol Cell Biol 2001;21:5082–93.[Abstract/Free Full Text]
  14. Rabinovitz I, Tsomo L, Mercurio AM. Protein kinase C-{alpha} phosphorylation of specific serines in the connecting segment of the ß4 integrin regulates the dynamics of type II hemidesmosomes. Mol Cell Biol 2004;24:4351–60.[Abstract/Free Full Text]
  15. Mainiero F, Pepe A, Yeon M, Ren Y, Giancotti FG. The intracellular functions of {alpha}6ß4 integrin are regulated by EGF. J Cell Biol 1996;134:241–53.[Abstract/Free Full Text]
  16. Falcioni R, Antonini A, Nisticò P, et al. {alpha}6ß4 and {alpha}6ß1 integrins associate with ErbB-2 in human carcinoma cell lines. Exp Cell Res 1997;236:76–85.[CrossRef][Medline]
  17. Gambaletta D, Marchetti A, Benedetti L, et al. Cooperative signaling between {alpha}(6)ß(4) integrin and ErbB-2 receptor is required to promote phosphatidylinositol 3-kinase-dependent invasion. J Biol Chem 2000;275:10604–10.[Abstract/Free Full Text]
  18. Hellyer NJ, Cheng K, Koland JG. ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem J 1998;333:757–63.
  19. Wallasch C, Weiss FU, Niederfellner G, et al. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 1995;14:4267–75.[Medline]
  20. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341–54.[CrossRef][Medline]
  21. Holbro T, Beerli RR, Maurer F, et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 2003;100:8933–8.[Abstract/Free Full Text]
  22. Bon G, Folgiero V, Bossi G, et al. The loss of ß4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation. Clin Cancer Res 2006;12:3280–7.[Abstract/Free Full Text]
  23. Langhofer M, Hopkinson SB, Jones JC. The matrix secreted by 804G cells contains laminin-related components that participate in hemidesmosome assembly in vitro. J Cell Sci 1993;105:753–64.[Abstract]
  24. DeFatta RJ, Nathan CA, De Benedetti A. Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line. Laryngoscope 2000;110:928–33.[CrossRef][Medline]
  25. Bachelder RE, Ribick MJ, Marchetti A, et al. p53 inhibits {alpha}6ß4 integrin survival signaling by promoting the caspase 3-dependent cleavage of AKT/PKB. J Cell Biol 1999;147:1063–72.[Abstract/Free Full Text]
  26. Nguyen BP, Gil SG, Carter WG. Deposition of laminin 5 by keratinocytes regulates integrin adhesion and signaling. J Biol Chem 2000;275:31896–907.[Abstract/Free Full Text]
  27. Hintermann E, Yang N, O'Sullivan D, Higgins JM, Quaranta V. Integrin {alpha}6ß4-erbB2 complex inhibits haptotaxis by up-regulating E-cadherin cell-cell junctions in keratinocytes. J Biol Chem 2005;280:8004–15.[Abstract/Free Full Text]
  28. Hellye NJ, Cheng K, Koland JG. ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem J 1998;333:757–63.
  29. Hellyer NJ, Kim M-S, Koland JG. Heregulins-dependent Activation of Phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 Co-receptor. J Biol Chem 2001;276:42153–61.[Abstract/Free Full Text]
  30. Chung J, Bachelder RE, Lipscomb EA, Shaw LM, Mercurio AM. Integrin ({alpha}6ß4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells. J Cell Biol 2002;158:165–74.[Abstract/Free Full Text]
  31. Sekulic A, Hudson CC, Homme JL, et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 2000;60:3504–13.[Abstract/Free Full Text]
  32. De Benedetti A, Harris AL. eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol 1999;31:59–72.[CrossRef][Medline]
  33. Beretta L, Gingras AC, Svitkin YV, Hall MN, Sonenberg N. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J 1996;15:658–64.[Medline]
  34. Lipscomb EA, Simpson KJ, Lyle SR, Ring JE, Dugan AS, Mercurio AM. The {alpha}6ß4 integrin maintains the survival of human breast carcinoma cells in vivo. Cancer Res 2005;65:10970–6.[Abstract/Free Full Text]
  35. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159–67.[CrossRef][Medline]
  36. Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 1999;18:2149–64.[CrossRef][Medline]
  37. Xue C, Liang F, Mahmood R, et al. ErbB3-Dependent Motility and Intravasation in Breast Cancer Metastasis. Cancer Res 2006;66:1418–26.[Abstract/Free Full Text]
  38. Sweeney C, Carraway KL III. Negative regulation of ErbB family receptor tyrosine kinases. Br J Cancer 2004;90:289–93.[CrossRef][Medline]
  39. Yen L, Benlimame N, Nie ZR, et al. Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. Mol Biol Cell 2002;13:4029–44.[Abstract/Free Full Text]
  40. Gagnoux-Palacios L, Dans M, van't Hof W, et al. Compartmentalization of integrin {alpha}6ß4 signaling in lipid rafts. J Cell Biol 2003;162:1189–96.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
G. Bon, S. E. Di Carlo, V. Folgiero, P. Avetrani, C. Lazzari, G. D'Orazi, M. F. Brizzi, A. Sacchi, S. Soddu, G. Blandino, et al.
Negative Regulation of {beta}4 Integrin Transcription by Homeodomain-Interacting Protein Kinase 2 and p53 Impairs Tumor Progression
Cancer Res., July 15, 2009; 69(14): 5978 - 5986.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
V. Bhatia, R. V. Mula, N. L. Weigel, and M. Falzon
Parathyroid Hormone-Related Protein Regulates Cell Survival Pathways via Integrin {alpha}6{beta}4-Mediated Activation of Phosphatidylinositol 3-Kinase/Akt Signaling
Mol. Cancer Res., July 1, 2009; 7(7): 1119 - 1131.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Dentelli, A. Rosso, A. Zeoli, R. Gambino, L. Pegoraro, G. Pagano, R. Falcioni, and M. F. Brizzi
Oxidative Stress-mediated Mesangial Cell Proliferation Requires RAC-1/Reactive Oxygen Species Production and beta4 Integrin Expression
J. Biol. Chem., September 7, 2007; 282(36): 26101 - 26110.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Folgiero, V.
Right arrow Articles by Mercurio, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Folgiero, V.
Right arrow Articles by Mercurio, A. M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online